[Form 4] Cryo-Cell International Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cryo-Cell International’s Chairman, Co-CEO and 10% owner David Portnoy reported indirect open-market purchases totaling 19,301 shares of common stock. The buys, made through retirement and similar accounts on August 15, 18 and 19, 2025, were executed at weighted-average prices ranging from about $4.23 to $4.50 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 19,301 shares ($85,078)
Net Buy
20 txns
Insider
PORTNOY DAVID
Role
Chairman, Co-CEO
Bought
19,301 shs ($85K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 885 | $4.37 | $4K |
| Purchase | Common Stock | 9,327 | $4.37 | $41K |
| Purchase | Common Stock | 2,671 | $4.50 | $12K |
| Purchase | Common Stock | 6,418 | $4.43 | $28K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 135,721 shares (Indirect, By 401K);
Stock Option — 26,243 shares (Direct);
Common Stock — 804,742 shares (Direct)
Footnotes (1)
- Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. The price reported is a weighted average price. These shares were purchased in multiple transactions at $4.50. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.34 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.23 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
